Description
The test is used for the diagnosis of BRCA1-, BRCA2-, CHEK2-, PALB2-, NBN-associated oncological diseases, as well as for determining indications for personalized targeted therapy with PARP inhibitors.
Period of execution
Within 11 days. The specified time does not include the day of biomaterial collection
Biomaterial type